# Prenatal Phthalate Exposure and Neurodevelopmental Impairment

## The Mount Sinai Children's Environmental Health Study Project 2, 1998 – 2008

Stephanie M Engel, PhD Associate Professor, Department of Preventive Medicine Mount Sinai School of Medicine





- 1. Prenatal Phthalates & Neurodevelopment: Results from the Mount Sinai Children's Environmental Health and Disease Prevention Research Center
- 2. Strength of the evidence
- 3. Prenatal period as window of vulnerability
- 4. Strengths & limitations of prospective cohort designs for investigating prenatal environmental toxicant exposures

### 

# **Network of NIEHS/EPA funded Centers**



## **Phthalates and the Environment**

- Estimates of worldwide production range from 3 to 5.5 million tons per year
- Used in a wide range of consumer products
  - Plasticizers
  - Fragrance carrier
  - Solvents, adhesives, lubricants
- Ubiquitous exposure

- Endocrine disruptors
- ✓ Reproductive toxicants
- ✓ Relevance to Neurodevelopment
  - In experimental animals phthalates have been shown to reduce circulating thyroid hormone
  - High phthalate concentrations linked with low circulating thyroid hormone in adult men and in pregnant women

# New York Children's Environmental Health Study



### **NYCEHS Longitudinal Measures**

Prenatal Exposure Questionnaire Maternal Blood Maternal Urine

╢

Birth Cord Blood BNBAS Birth size measures

#### 1-2 year visits

Exposure Questionnaire and growth

Child urine Bayley Scales of Infant Development Infant and Toddler Behavior Questionnaires

> 4, 6 and 7-9 year visits Exposure Questionnaire and growth Child urine and Maternal Saliva WISC or WPPSI BASC, BRIEF and SRS

## **Prenatal Phthalate Exposure and Orientation**



Linear decline in mean orientation score with increasing concentrations of high molecular weight phthalates among girls. Boys and girls similar below 1 uM. Adjusted for Race, examiner, urinary creatinine

### High Molecular Weight Phthalate Exposure and Quality of Alertness



<u>Quality of Alertness</u>, overall quality of the infant's responsiveness Adjusted for Race, examiner, urinary creatinine

## **Prenatal LMWP and BASC-PRS Scales**

**Overall Effects of LMWP on Behavior** 



Engel SM et al., EHP 2010

## **Prenatal LMWP, Sex, and BASC-PRS Scales**



BASC Domain	LMWP p-value	At-Risk or Clinically Significant Scales by Childhood Clinical Groups		
		Conduct Disorder	ADHD	
Clinical Scales				
Aggression	**	$\checkmark$	✓	
Anxiety				
Attention Problems	**		✓	***
Atypicality	*		*	** p < 0.01 ** p < 0.05
Conduct Problems	***	$\checkmark$	✓	* p < 0.1
Depression	**	$\checkmark$	✓	
Hyperactivity	*	$\checkmark$	✓	
Somatization				
Withdrawal				
Adaptive Scales				
Adaptability	**	$\checkmark$	✓	
Leadership				
Social Skills	*			
Composite Scales				
Externalizing Problems	***	$\checkmark$	1	
Internalizing Problems				
Adaptive Skills	*	✓	✓	
Behavioral Symptom Index	***	$\checkmark$	✓	

SRS measures a range of social impairments present in the general population, and consistent with a number of child psychiatric conditions, including Autism Spectrum Disorders, PDD-NOS, ADHD and schizoid personality disorder of childhood.

### Subscales include:

- <u>Social Awareness</u>: Ability to pick up on social cues
- <u>Social Cognition</u>: Ability to interpret social cues
- <u>Social Communication</u>: Motoric aspects of reciprocal social behavior
- <u>Social Motivation</u>: Motivation to engage in social-interpersonal behavior
- <u>Autistic Mannerisms</u>: Stereotypical behaviors or restricted interests

LMWP Biomarker (log)	Beta	95% CI
Total Score	1.53	0.25, 2.82
Awareness	1.25	0.59, 2.13
Cognition	1.40	0.07, 2.74
Communication	1.86	0.48, 3.24
Motivation	0.83	-0.35, 2.02
Mannerisms	0.88	-0.50, 2.26

### Evaluating the evidence for phthalates and neurodevelopment-- strengths

- 1. Biological Plausibility
  - Disruption of maternal prenatal thyroid hormone a potential mechanism
  - Consequences of severe hypothyroxinemia during pregnancy include significant neurodevelopmental impairment
  - Evidence emerging that subclinical hypothyroxenima is also a threat to neurodevelopment

### 2. Dose-Response

- Both our examination of the BNBAS and the Behavioral screening instruments indicate that higher exposure was associated with more symptoms
- 3. Temporality
  - Biomarker of exposure in the prenatal period very clearly preceded the outcome and was well aligned with a vulnerable window of development.

### Evaluating the evidence for phthalates and neurodevelopment-- weaknesses

### 1. Replication

- No published replication with prenatal markers of exposure, but multiple studies underway
- 2. Experimental evidence
  - We cannot randomize people to exposures

#### **Examples**

- People choose to apply pesticides in their home
- People choose to use scented products or cosmetics
- People eat seafood containing contaminants
- No published animal studies that have investigated phthalates with attention

## **Prenatal Period as Window of Vulnerability**

"Susceptibility to teratogens varies with the developmental stage at the time of exposure"

**Example: Congenital Rubella Syndrome** 

- ≤12 weeks: Severe congenital anomalies: cataracts, deafness, cardiac, neurological
- 13-16 weeks: MILDER: deafness, mild neurological problems
- > 16 weeks: no symptoms at birth, impaired development

Other toxicants with epidemiological data supporting long-term impacts of prenatal exposure:

• Alcohol, cocaine, tobacco smoke, DES, valproic acid, thalidomide, methylmercury, lead, organophosphates...

### Lessons Learned from the NIEHS/EPA Children's Environmental Health Centers

• It may not be possible to accurately measure historical exposure from specimens or data collected after the outcome occurs

Regulatory changes in environmental chemicals Persistence of biomarker over time Accuracy of recall

• Context is key

The same magnitude of exposure may impact two individuals differently

Genetic Susceptibility Sex-specific effects

Parenting & home environment Lifestyle factors, diet or obesity Difficult to assess without prospectively collected data

### The Promise & the Burden of Prospective Birth Cohorts

- Required to obtain specimens from critical windows of development
- More accurately reflect the context of exposure during critical windows
- Other approaches may be preferable for rare disease & rare exposures
- Bio & Data repositories from prospective cohorts are costly and burdensome to assemble & maintain
- Provide the greatest flexibility to pursue other outcomes and exposures of interest in the future, perhaps not originally considered

### **Project 2 contributors**

Stephanie Engel, PhD Mary Wolff, PhD Richard Canfield, PhD Amir Miodovnik, MD Chenbo Zhu, MS Manori Silva, PhD Antonia Calafat, PhD Julie Britton, PhD Trudy Berkowitz, PhD Susan Teitelbaum, PhD Jim Wetmur, PhD Jia Chen, PhD Martha Lievano Stefanie Meisel Rochelle Osborne Dana B Barr, PhD

CEH: Grant Support NIEHS (ES009584), EPA (R827039 and RD831711), ATSDR, and The New York Community Trust